Editorials

• Transthyretin Cardiac Amyloidosis: From Rare Monogenic Disease to Common Pathway in Heart Failure?

  Verónica Culotta, James C. Moon

  Rev Esp Cardiol. 2016;69:888-9

• Natriuretic Peptides: Consensus Call for Use

  Domingo A. Pascual Figal, Jordi Casademont, José María Lobos, Pascual Piñera, Antoni Bayes-Genis, Jordi Ordóñez llanos, José Ramón González-Juanatey

  Rev Esp Cardiol. 2016;69:817-9

• What Should We Target in Heart Failure: Hemoglobin or Iron?

  Nael Hawwa, W.H. Wilson Tang

  Rev Esp Cardiol. 2016;69:811-2

• Aortic Calcium Score and Vascular Atherosclerosis in Asymptomatic Individuals: Beyond the Coronary Arteries

  José F. Rodríguez-Palomares, Artur Evangelista Masip

  Rev Esp Cardiol. 2016;69:813-6

• Bivalirudin Versus Unfractionated Heparin for Acute Coronary Syndromes: Do We Have a Winner?

  Giuseppe Gargiulo, Marco Valgimigli

  Rev Esp Cardiol. 2016;69:721-4

• Domino Effect in Quality of Care: Improving One Aspect of a Disease Can Improve Its Entire Spectrum

  Rosa-Maria Lidón

  Rev Esp Cardiol. 2016;69:730-1

• Peri-procedural Myocardial Infarction: If You Don’t Take a Temperature, You Can’t Find a Fever

  Philip D. Adamson, Nicholas L. Mills

  Rev Esp Cardiol. 2016;69:725-9

• The Social Impact of Cardiology Research: Beyond Management

  Gaietà Permanyer-Miralda, Saba Hinrichs-Krapels, Paula Adam

  Rev Esp Cardiol. 2016;69:639-43

• Neprilysin: Indications, Expectations, and Challenges

  Antoni Bayes-Genis, Josep Lupón

  Rev Esp Cardiol. 2016;69:647-9

• Echocardiography Outside the Cardiology Setting. Position Paper and Recommendations of the Spanish Society of Cardiology

  Joaquín Barba Cosials, Leopoldo Pérez de Isla

  Rev Esp Cardiol. 2016;69:644-6

• A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill

  José Ramón González-Juanatey, José María Mostaza, José María Lobos, Benjamín Abarca, José Luis Llisterri

  Rev Esp Cardiol. 2016;69:547-50

• On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013

  Inmaculada Roldán, Francisco Marín, on behalf of the Cardiovascular Thrombosis Group of the Spanish Society of Cardiology and the proposal development CommitteeSpanish Society of Cardiology (SEC), Spanish Thrombosis and Hemostasis Society (SETH), Spanish Society of Neurology (SEN), Spanish Society of Emergency Medicine (SEMES), Spanish Society of Internal Medicine (SEMI), Spanish Society of Primary Care Physicians (SEMERGEN)

  Rev Esp Cardiol. 2016;69:551-3

• Bioresorbable Vascular Scaffolds in Coronary Bifurcation Lesions: Only in Expert Hands

  Roisin Colleran, Robert A. Byrne

  Rev Esp Cardiol. 2016;69:543-6

• Visually-guided Laser Balloon Ablation of Atrial Fibrillation: A “Real World” Experience

  Rahul Bhardwaj, Vivek Y. Reddy

  Rev Esp Cardiol. 2016;69:474-6

• Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We’re Beginning to Know Who Will Benefit

  Juan M. Ruiz-Nodar

  Rev Esp Cardiol. 2016;69:471-3

• Integrating Multimodal Imaging in Clinical Practice: The Importance of a Multidisciplinary Approach

  José F. Rodríguez-Palomares, Miguel A. García Fernández, Joaquín Barba Cosials

  Rev Esp Cardiol. 2016;69:477-9

• Cost-effectiveness Analysis: Why and How

  Carlos Campillo-Artero, Vicente Ortún

  Rev Esp Cardiol. 2016;69:370-3

• Premature Ventricular Complex-induced Cardiomyopathy

  Rakesh Latchamsetty, Frank Bogun

  Rev Esp Cardiol. 2016;69:365-9

• Should We Anticoagulate Patients at High Risk of Atrial Fibrillation?

  Manuel Martínez-Sellés, Ignacio Fernández Lozano, Adrian Baranchuk, Antoni Bayes-Genis, Antonio Bayés de Luna

  Rev Esp Cardiol. 2016;69:374-6

• The Healthcare of Patients With Acute and Critical Heart Disease. Position of the Spanish Society of Cardiology

  Fernando Worner, Alberto San Román, Pedro Luis Sánchez, Ana Viana Tejedor, José Ramón González-Juanatey

  Rev Esp Cardiol. 2016;69:239-42